Dr.Β YuankaiΒ Shi
MD, PhD
Chief Physician & Professor of Medical Oncology
corporate_fareNational Cancer Center / CAMS Cancer Hospital, Beijing
Yuankai Shi
MD, PhD
Prof. Yuankai Shi (η³θΏε―), MD, PhD, is a senior medical oncologist and lymphoma specialist at the National Cancer Center and Cancer Hospital of the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing. He is a chief physician, professor and doctoral supervisor with a long-standing focus on lymphoma, hematologic malignancies and the clinical development of innovative anticancer medicines.
Over a career spanning more than two decades, Prof. Shi has helped shape the practice of medical oncology and anticancer drug research in China. His clinical work covers chemotherapy, targeted therapy, immunotherapy and clinical trials of new medicines, with particular depth in Hodgkin lymphoma, non-Hodgkin lymphoma and multiple myeloma. He has led nationally important clinical research, including the ORIENT-1 study of the anti-PD-1 immunotherapy sintilimab in relapsed or refractory classical Hodgkin lymphoma. He is a frequent author and editor of Chinese cancer treatment guidelines and expert consensus documents, and is recognised for supporting the introduction of new treatment options for patients with difficult-to-treat cancers. His profile is especially relevant for patients with newly diagnosed, relapsed or refractory lymphoma who are weighing intensive treatment decisions or exploring clinical-trial options in China.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Shi, subject to hospital availability and case acceptance.
Why Consider Prof. Yuankai Shi?
Prof. Shi combines senior clinical experience in lymphoma and hematologic cancers with a leading role in China's anticancer drug research, making him a strong choice for complex and relapsed disease.
Areas of Specialization
Lymphoma, hematologic malignancies and systemic anticancer therapy
Prof. Shi focuses on the systemic treatment of lymphoma and selected hematologic cancers, with strong experience in immunotherapy, targeted therapy and clinical trials of new medicines for patients with limited standard-of-care options.
Lymphoma Management
Comprehensive systemic treatment of Hodgkin and non-Hodgkin lymphomas, including relapsed and refractory disease.
- arrow_rightHodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL)
- arrow_rightFollicular, peripheral T-cell and NK/T-cell lymphoma
- arrow_rightTreatment planning based on pathology, staging and PET-CT findings
- arrow_rightAssessment of disease that has not responded to first- or second-line therapy
- arrow_rightSalvage and combination regimens for difficult-to-treat disease
- arrow_rightEvaluation for immunotherapy and clinical-trial options
Immunotherapy & Targeted Therapy
Advanced systemic approaches for hematologic malignancies and selected cancers.
- arrow_rightAnti-PD-1 immunotherapy for suitable lymphoma patients
- arrow_rightTreatment selection guided by pathology and disease history
- arrow_rightChemotherapy and combination regimens
- arrow_rightTargeted agents for selected hematologic and solid tumours
Multiple Myeloma & Other Hematologic Cancers
Systemic treatment planning for multiple myeloma and complex hematologic malignancies.
- arrow_rightSystemic treatment planning for newly diagnosed and relapsed disease
- arrow_rightCoordination of multidisciplinary management
Procedures Performed
Clinical services and treatment approaches
Prof. Shi's practice centres on the systemic medical treatment of lymphoma and hematologic cancers, supported by molecular diagnostics, careful monitoring and access to clinical research.
Systemic Cancer Treatment
Medical OncologyTreatment planning and administration of systemic therapy for lymphoma and hematologic malignancies.
Immunotherapy & Targeted Therapy
Targeted TherapyCheckpoint-inhibitor and targeted treatment planning for suitable lymphoma and hematologic cancer patients.
Relapsed & Refractory Disease Management
Complex DiseaseEvaluation and treatment strategy for lymphoma and hematologic cancers that have not responded to standard therapy.
Diagnostic & Staging Work-Up
DiagnosisReview of pathology and imaging to confirm diagnosis and guide treatment.
Second Opinion Consultations
Second OpinionIndependent expert review of pathology, imaging and prior treatment for lymphoma and hematologic cancers.
Research & Publications
Lymphoma immunotherapy research and anticancer drug development
Prof. Shi is recognised as a leading clinical researcher in anticancer drug development in China, with a particular focus on immunotherapy and new treatment options for lymphoma.
For eligible patients, CancerFax can help review whether relevant clinical-trial options may be available in China, subject to hospital assessment and case acceptance.
Education & Training
Prof. Shi completed his medical and oncology training in China and undertook further academic and research experience internationally.
Clinical Experience
Prof. Shi has more than two decades of experience in medical oncology at one of China's leading national cancer centres, combining clinical care with anticancer drug research.
Languages & International
Prof. Shi consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients consulting Prof. Shi.
CancerFax can coordinate professional medical interpreter support for international patients where required.
How CancerFax Helps You Access Dr. Yuankai Shi
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Yuankai Shi's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Yuankai Shi's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Yuankai Shi before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Yuankai Shi's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Yuankai Shi's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Yuankai Shi's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Yuankai Shi
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Prof. Shi, subject to hospital availability and case acceptance. The CancerFax team also helps with interpreter support and travel-related coordination where required.
Prof. Shi focuses on lymphoma and hematologic malignancies, including Hodgkin lymphoma, non-Hodgkin lymphoma (such as DLBCL, follicular, peripheral T-cell and NK/T-cell lymphoma), relapsed or refractory lymphoma, and multiple myeloma. His work also covers systemic anticancer treatment and clinical trials of new medicines.
Submit your medical reports through CancerFax using the 'Send Your Reports' option. The CancerFax team will review the documents, prepare the case for submission, and coordinate the next steps with the hospital, subject to availability and case acceptance.
Yes. A second-opinion request can be submitted through CancerFax with the patient's pathology reports, lymphoma subtype, PET-CT or other imaging, and treatment history. The final consultation format and availability depend on the doctor's institution.
Yes. Prof. Shi is an experienced anticancer drug trialist who led the multicentre ORIENT-1 study of the anti-PD-1 immunotherapy sintilimab in relapsed or refractory classical Hodgkin lymphoma. For eligible patients, CancerFax can help review whether relevant trial options may be available in China, subject to hospital assessment.
Relapsed or refractory lymphoma is a particular area of focus for Prof. Shi. He can review prior treatment, pathology and imaging to assess salvage and combination strategies, immunotherapy options, and possible eligibility for clinical trials, helping patients understand the realistic next steps that require full investigation and oncology review.
Connect with Yuankai Shi Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.